<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963155</url>
  </required_header>
  <id_info>
    <org_study_id>NKPROSTATE-IPC 2015-019</org_study_id>
    <nct_id>NCT02963155</nct_id>
  </id_info>
  <brief_title>Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration</brief_title>
  <acronym>NKPROSTATE</acronym>
  <official_title>Prospective Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective research of Natural Killer cells as predictive biomarkers to stratify patients
      likely to have longer response time to castration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to validate prospectively the results of a retrospective study showing
      a correlation between the level of NKp30 and NKp46 receptor-activators expression on the
      surface of NK cells and 1) the survival time, 2) the response time to castration in patients
      with metastatic prostate cancer.

      Prospective monocenter, open-label study.

      During a visit in the frame of management of the disease, a single blood sample will be
      collected. Patients will then have a standard care follow-up for a period of 5 years. Follow
      up data (death, progression) will be collected every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response time to castration</measure>
    <time_frame>every 6 months during 3 years-follow up</time_frame>
    <description>Time of occurrence of:
confirmed PSA rise + serum testosterone &lt; 0.50 ng/mL
and/or radiological progression according to the modified PCWG2 criteria (progression according to the RECIST criteria v1.1 or documented by the appearance of at least 2 new lesions on the bone scan)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>every 6 months during 3 and 5 years-follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of alcaline phosphatase</measure>
    <time_frame>at diagnostic (before inclusion in the study) and at time of treatment for progression in the course of 3 years-follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor volume</measure>
    <time_frame>at diagnostic (before inclusion in the study)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic prostate cancer blood samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Metastatic prostate cancer blood samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with metastatic prostate cancer.

          2. Aged of 18 years or more.

          3. Patient in period of sensitivity to castration (patient non castrated or castration
             performed less than 1 year ago) and lack of progression.

          4. Patient having signed an informed consent.

          5. Patient affiliated to the national &quot;Social Security&quot; regimen or beneficiary of this
             regimen.

        Exclusion Criteria:

          1. Patient under chemotherapy treatment at the time of sampling

          2. Patient under corticotherapy treatment at the time of sampling

          3. Patient in emergency situation, adult subject to a measure of legal protection (placed
             under judicial protection, tutorship, or curatorship), or unable to give consent.

          4. Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study medical follow-up

          5. Contraindications to study procedure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwenaelle GRAVIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>33 4 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle BOQUET, PhD.</last_name>
    <phone>33 4 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GENRE, MD</last_name>
      <phone>33 (0)4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle BOQUET, PhD.</last_name>
      <phone>33 (0)4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GRAVIS Gwénaëlle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://institutpaolicalmettes.fr</url>
    <description>official website of the sponsor</description>
  </link>
  <reference>
    <citation>Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 2015 Jun 10;6(16):14360-73.</citation>
    <PMID>25961317</PMID>
  </reference>
  <reference>
    <citation>Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009 Aug 31;348(1-2):9-17. doi: 10.1016/j.jim.2009.06.004. Epub 2009 Jun 22.</citation>
    <PMID>19552894</PMID>
  </reference>
  <reference>
    <citation>Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Epub 2011 Aug 15.</citation>
    <PMID>21841316</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate, metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

